360 related articles for article (PubMed ID: 32459922)
1. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
[TBL] [Abstract][Full Text] [Related]
2. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin Ligase Activities of WWP1 Germline Variants K740N and N745S.
Jiang H; Dempsey DR; Cole PA
Biochemistry; 2021 Feb; 60(5):357-364. PubMed ID: 33470109
[TBL] [Abstract][Full Text] [Related]
4. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
Bennett KL; Mester J; Eng C
JAMA; 2010 Dec; 304(24):2724-31. PubMed ID: 21177507
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J; Sesock K; Eng C
Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
[TBL] [Abstract][Full Text] [Related]
6. Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer.
Ngeow J; Ni Y; Tohme R; Song Chen F; Bebek G; Eng C
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1316-21. PubMed ID: 24712574
[TBL] [Abstract][Full Text] [Related]
7. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
Mester JL; Moore RA; Eng C
Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
[TBL] [Abstract][Full Text] [Related]
8. Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.
Brewer T; Yehia L; Bazeley P; Eng C
Am J Hum Genet; 2022 Aug; 109(8):1520-1533. PubMed ID: 35931053
[TBL] [Abstract][Full Text] [Related]
9. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
Ngeow J; Eng C
Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
[TBL] [Abstract][Full Text] [Related]
10. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.
Mester JL; Tilot AK; Rybicki LA; Frazier TW; Eng C
Eur J Hum Genet; 2011 Jul; 19(7):763-8. PubMed ID: 21343951
[TBL] [Abstract][Full Text] [Related]
11. Lifetime cancer risks in individuals with germline PTEN mutations.
Tan MH; Mester JL; Ngeow J; Rybicki LA; Orloff MS; Eng C
Clin Cancer Res; 2012 Jan; 18(2):400-7. PubMed ID: 22252256
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.
Ni Y; Zbuk KM; Sadler T; Patocs A; Lobo G; Edelman E; Platzer P; Orloff MS; Waite KA; Eng C
Am J Hum Genet; 2008 Aug; 83(2):261-8. PubMed ID: 18678321
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
[TBL] [Abstract][Full Text] [Related]
14. Copy Number Variation and Clinical Outcomes in Patients With Germline PTEN Mutations.
Yehia L; Seyfi M; Niestroj LM; Padmanabhan R; Ni Y; Frazier TW; Lal D; Eng C
JAMA Netw Open; 2020 Jan; 3(1):e1920415. PubMed ID: 32003824
[TBL] [Abstract][Full Text] [Related]
15. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
Orloff MS; Eng C
Oncogene; 2008 Sep; 27(41):5387-97. PubMed ID: 18794875
[TBL] [Abstract][Full Text] [Related]
16. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
[TBL] [Abstract][Full Text] [Related]
17. Germline PTEN mutations in Cowden syndrome-like families.
Marsh DJ; Dahia PL; Caron S; Kum JB; Frayling IM; Tomlinson IP; Hughes KS; Eeles RA; Hodgson SV; Murday VA; Houlston R; Eng C
J Med Genet; 1998 Nov; 35(11):881-5. PubMed ID: 9832031
[TBL] [Abstract][Full Text] [Related]
18. PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation?
Yehia L; Eng C
Hum Mol Genet; 2020 Oct; 29(R2):R150-R157. PubMed ID: 32568377
[TBL] [Abstract][Full Text] [Related]
19. Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.
Ngeow J; He X; Mester JL; Lei J; Romigh T; Orloff MS; Milas M; Eng C
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2320-7. PubMed ID: 23066114
[TBL] [Abstract][Full Text] [Related]
20. Cowden syndrome.
Gustafson S; Zbuk KM; Scacheri C; Eng C
Semin Oncol; 2007 Oct; 34(5):428-34. PubMed ID: 17920899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
